Spantide I

• Description :

  Spantide I, a substance P analog, is a selective NK1 receptor antagonist, with Ki values of 230 nM and 8150 nM for NK1 and NK2 receptor, respectively. Spantide I provides an approach to reduce type 1 and enhance the type 2 cytokine IL-10 in the infected cornea, leading to a significant reduction in corneal perforation[1][2][3].

• UNSPSC :

  12352209

• Target :

  Neurokinin Receptor

• Type :

  Peptides

• Related Pathways :

  GPCR/G Protein; Neuronal Signaling

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/spantide-i.html

• Purity :

  99.72

• Solubility :

  H2O : 100 mg/mL (ultrasonic)

• Smiles :

  CC(C)C[C@@H](C(N)=O)NC([C@H](CC(C)C)NC([C@@H](CC1=CNC2=CC=CC=C12)NC([C@H](CC3=CC=CC=C3)NC([C@H](NC([C@H](CCC(N)=O)NC([C@H](CCC(N)=O)NC([C@H]4N(CCC4)C([C@H](CCCCN)NC([C@H]5N(CCC5)C([C@H](N)CCCNC(N)=N)=O)=O)=O)=O)=O)=O)CC6=CNC7=CC=CC=C67)=O)=O)=O)=O

• Molecular Formula :

  C75H108N20O13

• Molecular Weight :

  1497.79

• References & Citations :

  [1]J C Beaujouan, et al. Higher potency of RP 67580, in the mouse and the rat compared with other nonpeptide and peptide tachykinin NK1 antagonists. Br J Pharmacol. 1993 Mar;108 (3) :793-800.|[2]M Zubrzycka, et al. Comparison of antagonistic properties of substance P analogs, spantide I, II and III, on evoked tongue jerks in rats. Endocr Regul. 2000 Mar;34 (1) :13-8.|[3]Linda D Hazlett, et al. Spantide I decreases type I cytokines, enhances IL-10, and reduces corneal perforation in susceptible mice after Pseudomonas aeruginosa infection. Invest Ophthalmol Vis Sci. 2007 Feb;48 (2) :797-807.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

• Scientific Category :

  Peptides

• Clinical Information :

  No Development Reported

• Isoform :

  NK1R; NK2R

• CAS Number :

  [91224-37-2]